Amylyx Pharmaceuticals, Inc.
AMLX Healthcare Drug Manufacturers Specialty & Generic
Amylyx Pharmaceuticals, Inc.’s revenue for fiscal 2024 (year ended December 2024) was $87.4 million, down 77.1% from fiscal 2023. In the quarter to June 2026, revenue fell 100.6%, EPS grew 15.2% and free cash flow fell 24.5%, each against the same quarter a year earlier. Insiders bought in the last twelve months.
Follow AMLX
Amylyx Pharmaceuticals, Inc. (AMLX) Dividend Safety Score
Amylyx Pharmaceuticals, Inc.'s Dividend Safety Score for fiscal 2024 cannot be worked out: does not pay a regular dividend.
Dividend Safety Score, annual
Annual newest first
| Period | Dividend Safety Score | Change (points) |
|---|
How fiscal 2024’s score is made up
| Component | This year | Year before | Result | Points |
|---|---|---|---|---|
| Payout of earnings earnings at or below zero | — | — | Fail | 0 |
| Payout of free cash flow free cash flow at or below zero | — | — | Fail | 0 |
| Net debt / EBITDA net cash | — | — | Pass | 20 |
| Years without a dividend cut | 0 | — | Fail | 0 |
| Years of falling or negative earnings over the last 4 fiscal years | 4 | — | Fail | 0 |
| Dividend Safety Score | n/a — does not pay a regular dividend | — | ||
How the stockrow Dividend Safety Score works
Our own composite, out of 100, for the latest fiscal year: up to 25 points for how little of its earnings the dividend takes, 25 for how little of its free cash flow, 20 for net debt against EBITDA, 20 for the years it has paid without a cut and 10 for how steady earnings per share have been over ten years. How we calculate it.
| 80–100 | Well covered |
|---|---|
| 60–79 | Adequately covered |
| 40–59 | Stretched |
| below 40 | Weakly covered |
Not worked out for a company that pays no regular dividend, for banks and REITs, whose payouts and leverage these measures do not describe, or with fewer than five years of earnings.
Dividend Safety Score against peers
| Company | Dividend Safety Score |
|---|---|
| PRGO Perrigo Company plc compare | 16 |
| PBH Prestige Consumer Healthcare Inc. compare | — |
| ALVO Alvotech compare | — |
| INDV Indivior Pharmaceuticals Inc. compare | — |
| AMLX Amylyx Pharmaceuticals, Inc. | — |
| LQDA Liquidia Corporation compare | — |
| SUPN Supernus Pharmaceuticals, Inc. compare | — |
| RGC Regencell Bioscience Holdings Limited compare | — |
| HCM HUTCHMED (China) Limited Sponsored ADR compare | — |
What Dividend Safety Score is
The stockrow Dividend Safety Score rates how well earnings and free cash flow cover the dividend, with leverage, the dividend’s record and stable earnings.
Up to 25 points for the payout of earnings, 25 for the payout of free cash flow, 20 for net debt ÷ EBITDA, 20 for the years without a dividend cut and 10 for stable earnings